PCM
NUVB icon

Penserra Capital Management’s Nuvation Bio NUVB Stock Holding History

Penserra Capital Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,914
Closed -$22K – 1140
2022
Q2 		$22K Sell
6,914
-104
-1% -$454 ﹤0.01% 1093
2022
Q1 		$36K Sell
7,018
-3,359
-32% -$18.9K ﹤0.01% 1096
2021
Q4 		$88K Sell
10,377
-6,009
-37% -$55.2K ﹤0.01% 868
2021
Q3 		$162K Sell
16,386
-20,974
-56% -$190K ﹤0.01% 656
2021
Q2 		$347K Buy
+37,360
New +$426K 0.01% 550

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Penserra Capital Management's NUVB Position: Q3 2022 in Review

Penserra Capital Management sold out of Nuvation Bio (NUVB) in Q3 2022, closing a stake of 6,914 shares — an estimated $22K sold.

Penserra Capital Management first reported a position in NUVB in Q2 2021 and held it in 5 quarters. The position peaked at $347K in Q2 2021. 121 funds tracked by Wall St. Rank hold NUVB as of Q3 2022.

  • Penserra Capital Management reported no remaining Nuvation Bio position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 6,914 Nuvation Bio shares in Q3 2022, an estimated $22K.
  • Penserra Capital Management first reported a position in Nuvation Bio in Q2 2021 and held it in 5 quarters.
  • Penserra Capital Management's Nuvation Bio position peaked at $347K in Q2 2021.
  • 121 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.